These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. Cheah CY; Opat S; Trotman J; Marlton P Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618 [TBL] [Abstract][Full Text] [Related]
4. Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study. Bommier C; Donzel M; Rossi C; Fornecker LM; Bijou F; Chauchet A; Lebras L; Ysabaert L; Haioun C; Bouabdallah K; Gastinne T; Morineau N; Amorim S; Jardin F; Abraham J; Lamy de la Chapelle T; Gressin R; Fouillet L; Fruchart C; Olivier G; Morschhauser F; Cherblanc F; Belot A; Le Guyader S; Monnereau A; Ghesquieres H; Thieblemont C Hematol Oncol; 2024 Nov; 42(6):e3314. PubMed ID: 39351974 [TBL] [Abstract][Full Text] [Related]
5. Contemporary management of nodal and primary splenic marginal zone lymphoma. Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091 [No Abstract] [Full Text] [Related]
11. Management of Marginal Zone Lymphoma: A Canadian Perspective. Peters A; Keating MM; Nikonova A; Doucette S; Prica A Curr Oncol; 2023 Feb; 30(2):1745-1759. PubMed ID: 36826096 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial. Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401 [TBL] [Abstract][Full Text] [Related]